Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this extension trial is to investigate the long-term safety and tolerability of NN1250 in combination with insulin aspart. This is done by comparing NN1250 + insulin aspart ± metformin ± pioglitazone to insulin glargine + insulin aspart ± metformin ± pioglitazone after 78 weeks of treatment (52 weeks of treatment in NN1250-3582 plus 26 weeks of treatment in this extension trial) in terms of the listed safety assessments from which endpoints will be calculated: • Adverse events. • Hypoglycaemic episodes. • Clinical evaluation. • Central laboratory assessments. • Body weight. • Insulin dose.
Critère d'inclusion
- Type 2 Diabetes